Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer

Trial ID: NCT06196671

Interventional - Phase 2 - Not yet recruiting

The purpose of this study is to evaluate the efficacy of oncolytic virus plus PD-1 inhibitor to Patients with Advanced Pancreatic Cancer.

Conditions

Ability to understand and the willingness to sign a written informed consent document.
Age ≥ 18 years and ≤ 80 years.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Histologically or cytologically confirmed advanced pancreas adenocarcinoma.
Patients who have received at least two lines of anti-tumor chemotherapy, or patients who have been unsuitable or unwilling to standard therapy.
Locally advanced, or metastatic pancreatic cancer.
Presence of at least of one measurable lesion in agreement to RECIST criteria.
The expected survival ≥ 3 months.
Adequate organ performance based on laboratory blood tests.
Patients who are willing or able to comply with study procedures.

Inflammation of the digestive tract, including pancreatitis, cholecystitis, cholangitis, etc.
Pregnant or nursing women.
Primary pancreatic cancer, or prior treatment with oncolytic virus and PD-1 inhibitor.
The diagnosis was confirmed by pathology as non-adenocarcinoma of pancreas.
Severe and uncontrollable accompanying diseases that may affect protocol compliance or interfere with the interpretation of results.
Allergic to study drugs.
Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment.

Fudan University